Charles River Laboratories International, Inc. (CRL)

Check out top investors' recommendation for CRL
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
117.00
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
100%/0%
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
Charles River Laboratories International, Inc., together with its subsidiaries, provides research models and associated services, and outsourced preclinical services to accelerate the drug discovery and development process. It operates in two segments, Research Models and Services (RMS), and Preclinical Services (PCS). The RMS segment is involved in the production and sale of research model strains, principally genetically and microbiologically defined purpose-bred rats and mice for use by researchers. This segment also offers a range of services to assist customers in the drug discovery and development process, which include genetically engineered models and services, insourcing solutions, discovery research services, research animal diagnostic services, endotoxin and microbial detection products and services, and avian vaccine products and services. The PCS segment provides preclinical services, including both in vivo and in vitro studies, supportive laboratory services, and strategic preclinical consulting and program management to support product development. This segment offers services in the areas of bioanalysis, pharmacokinetics, and drug metabolism; toxicology; and pathology services, as well as testing of biologics and devices frequently outsourced by pharmaceutical and biotechnology companies. The company serves pharmaceutical companies, biotechnology companies, government agencies, hospitals, and academic institutions worldwide. Charles River Laboratories International, Inc. was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Sector:
Industry:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Eric Coldwell Robert W. Baird & Co., Inc. Buy   Nov 13, '17     117.00  Nov 13, '18  N/A 
David Windley Jefferies & Co. Buy   Sep 11, '17     120.00  Sep 11, '18  N/A 
Eric Coldwell Robert W. Baird & Co., Inc. Buy   Aug 31, '17     114.00  Aug 31, '18  N/A 
David Windley Jefferies & Co. Buy   Jun 29, '17     121.00  Jun 29, '18  N/A 
David Windley Jefferies & Co. Buy   Jan 08, '16   78.95  96.00  Jan 08, '17  2.38% 
Tim Evans Wells Fargo Securities, Llc Buy   Jan 07, '16   78.52    Jan 07, '17  N/A 
Douglas Tsao Barclays Sell   Jul 10, '15   73.29    Jul 10, '16  -16.69% 
David Windley Jefferies & Co. Buy   Jul 10, '15   73.29    Jul 10, '16  16.69% 
Tim Evans Wells Fargo Securities, Llc Sell   Apr 07, '15   77.66    Apr 07, '16  -5.88% 
John Kreger William Blair & Company, L.L.C. Buy   Jan 23, '15   68.79    Jan 23, '16  9.68% 
David Windley Jefferies & Co. Buy   May 01, '14   51.45    May 01, '15  34.42% 
David Windley Jefferies & Co. Buy   Mar 14, '14   60.73    Mar 14, '15  32.04% 
Greg Bolan Sterne, Agee & Leach Buy   Nov 01, '13   49.61  60.00  Nov 01, '14  27.31% 
Eric Coldwell Robert W. Baird & Co., Inc. Buy   Oct 30, '13   48.55  53.00  Oct 30, '14  32.79% 
Robert Jones Goldman Sachs Sell   Jun 18, '13   42.56  38.00  Jun 18, '14  -26.88% 
Greg Bolan Sterne, Agee & Leach Buy   Jun 12, '13   42.14    Jun 12, '14  29.24% 
Alexander Draper Raymond James Sell   May 30, '13   44.02    May 30, '14  -21.79% 
Greg Bolan Sterne, Agee & Leach Buy   Jan 13, '13   41.33  51.00  Jan 13, '14  37.58% 
Eric Coldwell Robert W. Baird & Co., Inc. Buy   Dec 12, '12   35.65  43.00  Dec 12, '13  46.28% 
Michael Cherny ISI Group Sell   Jul 08, '12   32.69  34.00  Jul 08, '13  -4.01% 
< previous12